" 里程碑制药公司 " 推出52.5M股股票,为心脏病治疗提供资金。 Milestone Pharmaceuticals launches $52.5M stock offering to fund a heart disease treatment.

里程碑制药公司正在对公众提供的5 250万美元共同股份进行定价,并授权其资助临床开发和商业启动其治疗PSVT这种非正常心跳的药物etripamil。 Milestone Pharmaceuticals is pricing a public offering of $52.5 million in common shares and warrants to fund the clinical development and commercial launch of its drug etripamil for treating PSVT, a type of irregular heartbeat. 根据市场条件,预计2025年7月14日左右将关闭这项提议。 The offering, subject to market conditions, is expected to close around July 14, 2025. TD Cowen、Piper Sandler & Co.和Wells Fargo证券公司是联合书账管理人,H.C.Wainwright & Co.是首席经理。 TD Cowen, Piper Sandler & Co., and Wells Fargo Securities are joint book-running managers, with H.C. Wainwright & Co. as lead manager.